Cost-effectiveness Analysis of Screening Extremely Low Birthweight Children for Hepatoblastoma Using Serum Alpha-fetoprotein


For the estimated 55,699 children born at ELBW in the United States each year, this screening is associated with 77.7 additional quality-adjusted life-years (QALYs) at a cost of $8.7 million. This results in an ICER of about $112,000/QALY, which is considered cost-effective from a U.S. Societal perspective. For children diagnosed with hepatoblastoma, our model finds that the screening regimen is associated with 10.1% increase in survival, a 4.18 increase in expected QALYs, and a $245,184 decrease in expected cost.

Source link


Please enter your comment!
Please enter your name here